News for Healthier Living

Teaching the Immune System to Control HIV

Last year, results from an HIV clinical trial showed that some participants maintained viral control for nearly two years without daily antiretroviral therapy. Now, a follow-up study shows that long-acting broadly neutralizing antibodies, or bNAbs, working together with antibodies produced by a patient's immune system, may help explain these unprecedented results. The new analysis also shows that the treatment accelerated the decline of dormant HIV capable of restarting an infection, reducing its estimated half-life from many years to just 36 weeks. The latest findings point to a new strategy: using vaccination to prime the immune system to work with bNAbs, while designing novel antibody combinations that make it harder for HIV to develop resistance.

September 17, 2026


September 18 2026

September 17 2026

September 16 2026

September 15 2026

September 14 2026

September 11 2026

September 10 2026

September 9 2026

September 8 2026

September 7 2026

September 5 2026

September 4 2026